Seminars in Oncology
Volume 32, Issue 3 , Pages 279-283 , June 2005

Adjuvant Chemotherapy in Early-Stage Non-Small Cell Lung Cancer

References 

  1. Parkin DM , Bray F , Ferlay J , et al.   Estimating the world cancer burden (Globocan 2000) . Int J Cancer . 2001;94:153–156
  2. Mountain CF . Revisions in the Internationnal system for staging lung cancer . Chest . 1997;111:1711–1717
  3. Girling DJ , Stott H , Stephens RJ , et al.   Fifteen-year following of all patients in a study of postoperative chemotherapy for bronchial carcinoma . Br J Cancer . 1985;52:867–873
  4. Shields TW , Humphrey EW , Eastridge CE , et al.   Adjuvant chemotherapy after resection of carcinoma of the lung . Cancer . 1972;40:2057–2062
  5. Israel L , Bonadonna G , Sylvester R , et al.   Controlled study with adjuvant radiotherapy, chemotherapy, immunotherapy and chemoimmunotherapy in operable squamous carcinoma of lung . In:  Muggia F ,  Rozencweij M editor. Lung Cancer (Progress in Therapeutic Research) . New York, NY: Raven; 1979;p. 443–452
  6. Shields TW , Higgins GA , Humphrey EW , et al.   Prolonged intermittent adjuvant chemotherapy with CCNU and hydroxyurea after resection of carcinoma of the lung . Cancer . 1982;50:1713–1721
  7. Mountain CF , Vincent RG , Sealy R , et al.   A clinical trial of CCNU as surgical adjuvant treatmernt for patient with surgical stage I and stage II NSCLC (Preliminary findings) . In:  Muggia F ,  Rozencweij M editor. Lung Cancer (Progress in Therapeutic Research) . New York, NY: Raven; 1979;p. 421–431
  8. Holmes EC , for the LCSG . Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma . J Clin Oncol . 1986;4:710–715
  9. Feld R , for the LCSG . Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non small-cell lung cancer . J Natl Cancer Inst . 1993;85:299–306
  10. Niiranen A , Niitamo-Korhonen S , Kouri M , et al.   Adjuvant chemotherapy after radical surgery for non small-cell lung cancer (A randomised study) . J Clin Oncol . 1992;10:1927–1932
  11. Ohta M , Tsuchiya R , Shimoyama M , et al.   Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer . J Thorac Cardiovasc Surg . 1993;106:703–706
  12. Non small-cell Lung Cancer Collaborative Group . Chemotherapy in non small-cell lung cancer (A meta-analysis using updated data on individual patients from 52 randomized clinical trials) . Br Med J . 1995;1:899–909
  13. Keller SM , Adak S , Wagner H , et al.  Eastern Cooperative Oncology Group   Ramdomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non small- cell lung cancer . N Engl J Med . 2000;343:1217–1222
  14. PORT Meta-analysis Trialist’s Group . Postoperative radiotherapy in non small-cell lungcancer (Systematic review and meta-analysis of individual patient data from nine randomised controlled trials) . Lancet . 1998;352:257–263
  15. Scagliotti GV , Fossati  , Torni V , et al.  Adjuvant lung project Italy/European Organisation for Research Treatment of cancer/Lung Cancer Cooperative Group Investigators   Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIA non small-cell lung cancer . J Natl Cancer Inst . 2003;95:1453–1461
  16. International Adjuvant Lung Cancer Trial Collaborative Group . Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer . N Engl J Med . 2004;22(350):351–356
  17. Kato H , Ichinose Y , Ohta M , et al.   A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung . N Engl J Med . 2004;350:1713–1721
  18. Wada H , Hitomi S , Teramatsu T  West Japan Study Group for Lung Cancer Surgery . Adjuvant chemotherapy after complete resection in non-small-cell lung cancer . J Clin Oncol . 1996;14:1048–1054
  19. Hamada C , Ohta M , Wada H , et al.   Survival benefit of oral UFT for adjuvant chemotherapy after completely resected non-small-cell lung cancer . Proc Am Soc Clin Oncol . 2004;22:1124; (abstr 7002)
  20. Waller D , Fairlamb DJ , Gower N , et al.   The Big Lung Trial (BLT): Determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the surgical setting . Proc Am Soc Clin Oncol . 2003;22:632; (abstr 2543)
  21. Winton TL , Livingston R , Johnson D , et al.   A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10 . Proc Am Soc Clin Oncol . 2004;22:1127; (abstr 7018)
  22. Strauss GM , Herndon J , Maddaus MA , et al.   Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (Report of Cancer and Leukemia Group B (CALGB) Protocol 9633) . Proc Am Soc Clin Oncol . 2004;22:1128; (abstr 7019)
  23. Rosell R , Monzo M , O’Brate A , et al.   Translational oncogenomics (Toward rational therapeutic decision-making) . Curr Opin Oncol . 2002;14:171–179
  24. Rosell R , Monzo M , Alberola V , et al.   Determinants of response and resistance to cytotoxics . Semin Oncol . 2002;29(suppl):110–118
  25. Lord RV , Brabender J , Gandara D , et al.   Low ERCC1 expression corrlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small-cell lung cancer . Clin Cancer Res . 2002;8:2286–2291
  26. Scagliotti GV , de Marinis F , Rinaldi M , et al.   Phase III randomized trial comparing three platinum-based doublets in advanced non small cell cancer . J Clin Oncol . 2002;20:4285–4291
  27. Paez JG , Janne PA , Lee JC , et al.   EGFR mutations in lung cancer (Correlation with clinical response to gefitinib therapy) . Science . 2004;304:1497–1500
  28. Lynch TJ , Bell DW , Sordella R , et al.   Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib . N Engl J Med . 2004;350:2129–2139
  29. Pao W , Miller V , Zakowski M , et al.   EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib . Proc Natl Acad Sci U S A . 2004;101:13306–13311
  30. Cappuzzo F , Magrini E , Ceresoli GL , et al.   Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer . J Natl Cancer Inst . 2004;96:1133–1141
  31. Slamon DJ , Leyland-Jones B , Shak S , et al.   Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpression HER2 . N Engl J Med . 2001;344:783–792
  32. Verweij J , van Oosterom A , Blay JY , et al.   Imatinib mesylate is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target (Results from an EORTC soft-tissue and bone sarcoma group phase II study) . Eur J Cancer . 2003;39:2006–2011
  33. Ichinose Y , Genka K , Koike T , et al.   Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma . J Natl Cancer Inst . 2003;95:605–610
  34. Giaccone G , Herbst RS , Manegold C , et al.   Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer (A phase III trial—INTACT 1) . J Clin Oncol . 2004;22:777–784
  35. Herbst RS , Giaccone G , Schiller JH , et al.   Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer (A phase III trial—INTACT 2) . J Clin Oncol . 2004;22:785–794

PII: S0093-7754(05)00088-6

doi: 10.1053/j.seminoncol.2005.02.018

Seminars in Oncology
Volume 32, Issue 3 , Pages 279-283 , June 2005

Article Tools